Sanofi Offers Topline Results from Second PIVOTAL LixiLan Phase III Study
September 14, 2015 at 08:04 AM EDT
Sanofi (NYSE: SNY) announced today that the LixiLan-L Phase III clinical trial met its primary endpoint in patients with type 2 ...
